http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#Head http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA http://www.nanopub.org/nschema#hasAssertion http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#assertion http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA http://www.nanopub.org/nschema#hasProvenance http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#provenance http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA http://www.nanopub.org/nschema#hasPublicationInfo http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#pubinfo http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#assertion http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#_1 http://purl.obolibrary.org/obo/RO_0002204 http://www.informatics.jax.org/marker/MGI:98725 http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#_1 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080 http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#_2 http://purl.obolibrary.org/obo/BFO_0000066 http://disease-ontology.org/term/DOID:1936 http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#_2 http://purl.obolibrary.org/obo/BFO_0000066 http://purl.obolibrary.org/obo/CL_0000192 http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#_2 http://purl.obolibrary.org/obo/BFO_0000066 http://purl.obolibrary.org/obo/UBERON_0004535 http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#_2 http://purl.obolibrary.org/obo/BFO_0000066 http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=10090 http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#_2 http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://resource.belframework.org/belframework/20131211/namespace/selventa-legacy-diseases/Atherosclerotic%20lesion http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#_2 http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate http://www.selventa.com/vocabulary/decreases http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#_2 http://www.w3.org/1999/02/22-rdf-syntax-ns#subject http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#_1 http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#_2 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#assertion http://www.w3.org/2000/01/rdf-schema#label p(MGI:Tgfb1) -| path(SDIS:"Atherosclerotic lesion") http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#provenance http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://purl.org/dc/elements/1.1/description Approximately 61,000 statements. http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://purl.org/dc/elements/1.1/rights Copyright (c) 2011-2012, Selventa. All rights reserved. http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://purl.org/dc/elements/1.1/title BEL Framework Large Corpus Document http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://purl.org/pav/authoredBy http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#_4 http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://purl.org/pav/version 20131211 http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#_3 http://www.w3.org/ns/prov#value inhibition of endogenous TGF-?1 signaling in mice using either neutralizing monoclonal antibodies or soluble recombinant TGF-? receptor type II (TGF-?RII) accelerated atherosclerotic lesion formation characterized by increased macrophages and T cells, and decreased collagen content.30, 31 http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#_3 http://www.w3.org/ns/prov#wasQuotedFrom http://www.ncbi.nlm.nih.gov/pubmed/16462725 http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#_4 http://www.w3.org/2000/01/rdf-schema#label Selventa http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#assertion http://www.w3.org/ns/prov#hadPrimarySource http://www.ncbi.nlm.nih.gov/pubmed/16462725 http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#assertion http://www.w3.org/ns/prov#wasDerivedFrom http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#assertion http://www.w3.org/ns/prov#wasDerivedFrom http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#_3 http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA#pubinfo http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA http://purl.org/dc/terms/created 2014-07-03T14:32:56.033+02:00 http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA http://purl.org/pav/createdBy http://orcid.org/0000-0001-6818-334X http://www.tkuhn.ch/bel2nanopub/RAkuJIl2E8klVILfwyv6_qgIP1baNg_JNFvakPrA_CRjA http://purl.org/pav/createdBy http://orcid.org/0000-0002-1267-0234